
    
      The primary objective of this study is to determine the pharmacokinetic (PK) profile of 600
      mg oral TPOXX (3 Ã— 200-mg capsules) administered twice daily (BID) for 7 days in adult
      subjects weighing more than 120 kg to determine if a change in dosing regimen would be needed
      in these patients.

      Secondary:

      The secondary objective of this study is to evaluate the safety and tolerability of 600 mg
      oral TPOXX administered BID for 7 days in healthy adult subjects weighing more than 120 kg.
    
  